Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review

Miguel Quintana, José A. Toriz, Diego Novick (), Kyla Jones, Brenda S. Botello and Juan Alejandro Silva
Additional contact information
Miguel Quintana: Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social
José A. Toriz: Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social
Diego Novick: Eli Lilly and Company
Kyla Jones: Tecnología e Información para la Salud
Brenda S. Botello: Eli Lilly and Company
Juan Alejandro Silva: Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social

PharmacoEconomics - Open, 2018, vol. 2, issue 2, No 10, 201 pages

Abstract: Abstract Background Little evidence is available on the management and cost of treating patients with advanced or metastatic gastric cancer (GC). This study evaluates patient characteristics, treatment patterns, and resource utilization for these patients in Mexico. Methods Data were collected from three centers of investigation (tertiary level). Patients were ≥18 years of age, diagnosed between 1 January 2009 and 1 January 2015, had advanced or metastatic GC, received first-line fluoropyrimidine/platinum, and had ≥3 months follow-up after discontinuing first-line treatment. Data were summarized using descriptive statistics. Results The study sample totaled 180. Patients’ mean age was 57.2 years (±12.4) and 57.0% were male; 151 (83.9%) patients received second-line chemotherapy. A total of 16 and 19 regimens were identified in first- and second-line therapy. Of the sample, 51 (28.3%) received third-line therapy, and

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0043-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0043-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-017-0043-2

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().